A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine, in the prevention of oral persistent infection with HPV Types 16, 18, 31, 33, 45, 52, or 58 in adult males, 20 to 45 years of age

18, 31, 33, 45, 52, and 58, Prevention of oral persistent infection caused by any of the human papillomavirus types 16

Incidence of Human Papillomavirus (HPV)16/18/31/33/45/52/58-related 6-month Persistent Oral Infection

Incidence of HPV 6/11-related 6-month Persistent Oral Infection, Geometric Mean Titers to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 Antibodies, Percentage of Participants Who Seroconvert to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58, Percentage of Participants with at Least 1 Solicited Injection-site Adverse Event (AE), Percentage of Participants with Elevated Temperature (Fever), Percentage of Participants Who Report at Least 1 Systemic AE, Percentage of Participants Who Experience at Least 1 Serious Adverse Event, Percentage of Participants Who Experience at Least 1 Serious Vaccine-related AE

No related papers found yet.

Belgium, Czechia, France, Germany, Italy, Spain